TY - JOUR
T1 - N-methylnicotinamide is an endogenous probe for evaluation of drugdrug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K)
AU - Ito, S.
AU - Kusuhara, H.
AU - Kumagai, Y.
AU - Moriyama, Y.
AU - Inoue, K.
AU - Kondo, T.
AU - Nakayama, H.
AU - Horita, S.
AU - Tanabe, K.
AU - Yuasa, H.
AU - Sugiyama, Y.
PY - 2012/11
Y1 - 2012/11
N2 - Multidrug and toxin extrusion 1 (MATE1) and MATE2-K are H /organic cation exchangers mediating the efflux of cationic drugs into the urine. N-methylnicotinamide (NMN) was found to be an endogenous substrate of MATE1 (Michaelis constant (K m) 301 ± 18mol/l) and MATE2-K (K m 422 ± 63mol/l) as well as a basolateral influx transporter, organic cation transporter 2 (K m 318 ± 29mol/l). A potent MATE inhibitor, pyrimethamine, competitively inhibited the uptake by MATE1 and MATE2-K with inhibition constant (K i) values of 83 ± 15 and 56 ± 11 nmol/l, respectively. The uptake of NMN by human kidney brush border membrane vesicles with a H gradient was saturable (K m 360 ± 55mol/l) and completely inhibited by pyrimethamine. The renal clearance of endogenous NMN was 403 ± 61 in healthy male subjects, and it was significantly decreased to 119 ± 16 ml/min/kg by an oral dose of pyrimethamine (50 mg). These results support the utility of NMN as an endogenous in vivo probe for investigating MATE1 and MATE2-K in humans.
AB - Multidrug and toxin extrusion 1 (MATE1) and MATE2-K are H /organic cation exchangers mediating the efflux of cationic drugs into the urine. N-methylnicotinamide (NMN) was found to be an endogenous substrate of MATE1 (Michaelis constant (K m) 301 ± 18mol/l) and MATE2-K (K m 422 ± 63mol/l) as well as a basolateral influx transporter, organic cation transporter 2 (K m 318 ± 29mol/l). A potent MATE inhibitor, pyrimethamine, competitively inhibited the uptake by MATE1 and MATE2-K with inhibition constant (K i) values of 83 ± 15 and 56 ± 11 nmol/l, respectively. The uptake of NMN by human kidney brush border membrane vesicles with a H gradient was saturable (K m 360 ± 55mol/l) and completely inhibited by pyrimethamine. The renal clearance of endogenous NMN was 403 ± 61 in healthy male subjects, and it was significantly decreased to 119 ± 16 ml/min/kg by an oral dose of pyrimethamine (50 mg). These results support the utility of NMN as an endogenous in vivo probe for investigating MATE1 and MATE2-K in humans.
UR - http://www.scopus.com/inward/record.url?scp=84867869728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867869728&partnerID=8YFLogxK
U2 - 10.1038/clpt.2012.138
DO - 10.1038/clpt.2012.138
M3 - Article
C2 - 23047651
AN - SCOPUS:84867869728
SN - 0009-9236
VL - 92
SP - 635
EP - 641
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 5
ER -